The Liver Meeting 2014: Summary of Presentations on Genotype 3 HCV Infection from the 65th Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Held in Boston, MA, USA, on 7th-11th November, 2014 - European Medical Journal

Continue

The Liver Meeting 2014: Summary of Presentations on Genotype 3 HCV Infection from the 65th Annual Liver Meeting of the American Association for the Study of Liver Diseases (AASLD), Held in Boston, MA, USA, on 7th-11th November, 2014

Hepatology
Download PDF
Speakers:
Markus Peck,1 *Stanislas Pol2

1. Department of Gastroenterology and Hepatology, Medizinische Universität Wien (MedUniWien), Vienna, Austria
2. Department of Hepatology, Groupe Hospitalier Cochin-Saint Vincent De Paul, Université Paris Descartes, Inserm UMS20, Institut Pasteur, Paris, France
*Correspondence to [email protected]

Disclosure:

Prof Stanislas Pol has been a speaker for GSK, BMS, Boehringer Ingelheim, Janssen, Gilead, Roche, MSD, Sanofi, Novartis, Vertex, and AbbVie; has been a board member for GSK, BMS, Boehringer Ingelheim, Janssen, Gilead, Roche, MSD, Sanofi, Novartis, Vertex, and AbbVie; and received grants from BMS, Gilead, Roche, and MSD. Prof Markus Peck-Radosavljevic has acted as speaker for AbbVie, BMS, Boehringer-Ingelheim, GSK, Gilead, MSD, Novartis; he has been an advisor to AbbVie, BMS, Gilead, MSD, and Roche and has received grants from Gilead, MSD, and Roche.

Acknowledgements:

Medical writing assistance was provided by Dr Caroline Charles (Scilink Medical Writing, Biarritz, France).

Citation:
EMJ Hepatol. ;3[1]:27-34. DOI/10.33590/emjhepatol/10314801. https://doi.org/10.33590/emjhepatol/10314801.
Keywords:
American Association for the Study of Liver Diseases, AASLD, chronic hepatitis C, genotype 3, direct-acting antivirals, meeting highlights

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

After genotype 1 (GT1), genotype 3 (GT3) is the second most common hepatitis C virus (HCV) genotype worldwide, with an estimated worldwide prevalence of 54.3 million. As its high prevalence already  represents a significant burden, this genotype appears to be one of the most difficult to treat using all  oral therapies, which is of importance as it is associated with more rapid fibrosis progression and disproportionately increased risks of steatosis (fatty liver disease) and hepatocellular carcinoma.  Outstanding developments in clinical research in the last few years have led to the development of  direct-acting antivirals, but GT3 still represents a challenge yet to be addressed, and is a clear unmet medical need, especially with associated comorbidities (advanced, liver disease, pre and post-transplant patients, HIV/HCV co-infected patients). The 65th American Association for the Study of Liver Diseases Annual Meeting, The Liver Meeting® 2014, took place in Boston, Massachusetts, USA, on 7th–11th November 2014. This review will summarise the highlights of this meeting on the future of GT3 HCV treatment within  pivotal clinical trials.

Please view the full content in the pdf above.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given